Inhibitory mechanism of n-MTAB AuNPs for α-synuclein aggregation

Area of Science:

• Biochemistry
• Nanotechnology
• Neuroscience

Background:

• Alpha-synuclein (α-syn) aggregation is a critical factor in Parkinson's disease (PD) pathogenesis.
• Understanding the interaction between α-syn and therapeutic agents is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the potential of nanoparticle-mediated therapy for Parkinson's disease.
• To explore the interactive mechanism between α-syn and n-myristyltrimethylammonium bromide (MTAB) Gold nanoparticles (AuNPs) with varying diameters.

Main Methods:

• Molecular dynamics simulations were employed to study the interaction between α-syn and MTAB-AuNPs.
• Analysis of electrostatic and hydrophobic interactions guided the understanding of binding mechanisms.

Main Results:

• A directional interaction between α-syn and MTAB-AuNPs was observed, preventing α-syn aggregation.
• Electrostatic interactions drove the binding of α-syn's C-terminus, while the NAC domain showed weak hydrophobic and electrostatic interactions.
• Acidic amino acids (Glu, Asp) on 5-MTAB AuNPs were found to play a significant role.

Conclusions:

• This study provides a theoretical basis for understanding biomolecule adsorption onto biofunctional nanoparticles.
• 5-MTAB AuNPs demonstrate potential as an inhibitor of α-syn protein aggregation, offering a promising therapeutic avenue for Parkinson's disease.